Paterna BioSciences key facts
- Operator of a biotechnology company intended to develop an in vitro spermatogenesis process to improve human reproductive health.
- It has raised $8.0M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Tampa Bay Wave, Capita3, Divergent Capital (New York), Freya Ventures, MedTech Accelerator — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch Paterna BioSciences: the Monday email on marks, rounds and moves
Paterna BioSciences funding rounds
No funding rounds for Paterna BioSciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Paterna BioSciences investors
9 investors are on record for Paterna BioSciences, including Tampa Bay Wave, Capita3, Divergent Capital (New York) and Freya Ventures.
About Paterna BioSciences
Operator of a biotechnology company intended to develop an in vitro spermatogenesis process to improve human reproductive health. The company uses a patented process to isolate testicular spermatogonial stem cells and uses ligands and iterative chaperoned machine learning to guide spermatogenesis for intracytoplasmic sperm injection, enabling healthcare professionals to solve male infertility and improve offspring health.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2020
- Employees
- 22
- Website
- paternabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Paterna BioSciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.